Best Practices For Administering Monoclonal Antibody Therapy For Coronavirus (COVID-19)


Introduction

COVID-19 is a clinical syndrome due to infection with SARS-CoV-2. It has been discovered in Wuhan, China, in December 2019 and spread to a pandemic level in 2020. Globally it has affected more than 168 million people, with a death toll of more than 3.5 million patients. In the United States, the number of cases is more than 32 million, and the number of people who died from COVID-19 exceeded 586,000 patients (WHO Coronavirus dashboard as of 05/28/2021).

 Severe Acute Respiratory Syndrome Coronavirus-2 is one of the coronaviruses, single-stranded RNA viruses with close resemblance to the SARS outbreak of 2003.[1] SARS-CoV-2 differs from MERS(middle east respiratory syndrome) and SARS(Severe Acute Respiratory Syndrome)coronaviruses by easier spread and lower fatality rate.[2]

SARS-CoV-2 is transmitted by inhalation of air carrying droplets or from person to person through droplets spread by coughing, sneezing, singing, shouting, or even talking. In addition, SARS-CoV-2  has been detected on multiple services, and touching mucous membranes with hands contaminated with the SARS-CoV-2 virus may also be another transmission source. 

COVID -19 starts after an incubation period of around 5 days after exposure but could range from 2 to 14 days, and most of the patients can identify recent contact with COVID 19 patients. The clinical presentation varies from asymptomatic cases to severe symptoms of fatigue, headache, anosmia (loss of smell sensation), ageusia(loss of taste sensation), dyspnea, and dry cough that is persistent and may stimulate gag reflex and induce vomiting. Hypoxia that may worsen to require assisted ventilation, whether invasive or non-invasive.

The physical signs include fever, tachycardia, and hypoxia, resulting in acute respiratory failure and acute respiratory distress syndrome. Extrapulmonary manifestations have been described in many COVID patients, in multiple organ systems, including but not limited to:cutaneous: acral lesions, cardiovascular: myocardial injury and myocarditis, neurologic: headache and stroke, gastrointestinal: nausea, vomiting, and diarrhea, and elevated liver enzymes.[3]

The national institute of Health classifies the manifestations of SARS-CoV-2 as follows:

Asymptomatic or Presymptomatic Infection: positive testing for SARS-CoV-2 but no symptoms consistent with COVID-19.

Mild Illness: Individuals who have any of the various signs and symptoms of COVID-19 but do not have shortness of breath, dyspnea, or abnormal chest imaging.

Moderate Illness: the presence of lower respiratory disease and no hypoxia( oxygen saturation (SpO) ≥94% on room air).

Severe Illness: Hypoxia, Spo <94% on room air, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO/FiO) <300 mm Hg, respiratory frequency >30 breaths/min, or lung infiltrates >50%.

Critical Illness: Individuals who have respiratory failure, septic shock, and/or multiple organ dysfunction.

Mild to moderate cases of COVID-19 are usually managed on an outpatient basis. Patients requiring oxygen therapy to maintain their oxygenation are usually hospitalized and may require intensive care management for assisted ventilation, organ support, and treatment of secondary infection.

Management of non hospitalized patients with COVID-19 in the outpatient setting involves triaging the severity of symptoms and oxygen requirements. Identifying patients with risk factors for deterioration and close monitoring.

Patients without risk factors for deterioration are usually managed with supportive care and self-monitoring. Meanwhile, patients with risk factors for deterioration are offered Anti-SARS-CoV-2 monoclonal antibodies.

Function

Monoclonal antibodies are laboratory-made proteins that are derived from certain white blood cells. It has been used to treat certain autoimmune disorders, targeted cancer therapy, and some infections such as bezlotoxumab to treat recurrent Clostridioides difficile infection.

The most current therapeutic mAbs are IgGs(Immunoglobulins subtype G) due to ease of production and prolonged circulating half-life.[4]

Neutralizing antiviral monoclonal antibodies have been used clinically against Ebola virus disease (EVD), e.g., ZMapp[5], and respiratory syncytial virus (RSV) e.g.palivizumab. Due to that, monoclonal antibodies have been explored as an option against SARS-CoV-2.[6] Neutralizing antibodies can directly neutralize the virus without the aid of other immune factors or cells. The coronavirus engages the host cell receptor by the spike (S) glycoprotein to cause infection. That is why the spike S glycoprotein on the coronavirus surface is a common target for antiviral monoclonal antibodies.[7]

Anti-SARS-CoV2 antibodies are derived from the convalescent COVID -19 patients and were shown to decrease viral load in non-human primates in China and North America.[8]

The following combinations are given emergency use authorization by the FDA and recommended by the national institute of health and The Infectious Diseases Society of America for patients with mild to moderate COVID-19 who are at risk for medical deteriorations:

  • Bamlanivimab 700 mg plus etesevimab 1,400 mg ; or
  • Casirivimab 1,200 mg plus imdevimab 1,200 mg . 

Both combinations are given as one-time intravenous infusions with no dose adjustment is needed.

Bamlanivimab is a monoclonal human immunoglobulin G1 antibody, and it reduces the viral load of SARS-CoV2 and improves symptoms.[8] but due to the emergence of potentially resistant variants of SAR-CoV2, it is not recommended for monotherapy and has to be given in combination with Etesevimab. The combination of bamlanivimab and etesevimab was studied in patients with mild to moderate COVID -19 and was also found to reduce viral load and decrease the emergence of resistant strains.[9]

Bamlanimuvab monotherapy and in combination with Etsevimab was evaluated in ambulatory patients with mild to moderate COVID-19 pneumonia. The study published showed a decrease in the viral load of SARS-CoV-2, a decrease in ED visits, and hospitalization in patients who received the combination of Bamlanimuvab and Etsevimab.[9] 

While Bamlanimuvab has shown favorable benefits in patients with mild to moderate COVID-19, it failed to show benefits in hospitalized patients with COVID-19 pneumonia who have received remdesivir, oxygen therapy, and steroids when indicated.[10]

REGN-COV2 (casirivimab and imdevimab, administered together) is granted emergency use authorization for patients with mild to moderate COVID 19 not requiring oxygen and not hospitalized for COVID-19 management.

REGN-COV2 antibody cocktail was evaluated in non hospitalized patients with COVID-19, and the randomized controlled trial shows enhanced viral clearance and decreased rate of medically attended visits.[11]

Issues of Concern

According to COVID 19 treatment guidelines, High-risk groups for deterioration due to COVD-19 pneumonia, for which monoclonal antibodies are recommended, are stratified by age group:

  1.  65 years of age or above
  2.  55 years of age or above plus one of the following conditions: chronic respiratory disease, cardiovascular disease, or hypertension
  3.  12 to 17 years of age plus the following conditions: BMI more than or equal to 85th percentile for their age and gender, based on CDC growth charts. Sickle cell disease, congenital or acquired heart disease, neurodevelopmental disorder, chronic respiratory disease, or medically related technological dependence:e.g.tracheostomy, gastrostomy, or positive pressure ventilation.
  4.  Any age group with the following conditions: Body mass index more than or equal to 35, chronic kidney disease, diabetes, immunosuppressive disease, or currently receiving immunosuppressive treatment.

Possible adverse effects include anaphylaxis and infusion-related reactions, e.g.nausea, dizziness, pruritus, and rash.

The combination of bamlanivimab and etesevimab together had activity against the pseudovirus expressing del69-70 + N501Y found in B.1.1.7 variant (UK origin). The pseudovirus expressing spike protein from B.1.351 lineage (South Africa origin)  had reduced susceptibility to bamlanivimab and etesevimab together of >45-fold, and Thepseudovirus expressing K417T + E484K + N501Y found in the  P.1 lineage (Brazil origin) had reduced susceptibility to bamlanivimab and etesevimab together of >511-fold.

Clinical Significance

Indications for monoclonal antibodies in COVID-19 patients :

Anti-SARS-CoV-2 antibodies are indicated for use in non hospitalized patients with mild to moderate COVID-19 at high risk of deterioration. It is also indicated in patients with COVID-19 hospitalized for other conditions and at risk for deteriorating due to COVID-19. Anti-SARS-CoV-2 antibodies are not indicated in managing patients hospitalized with COVID-19 or requiring oxygen supplementation due to COVID-19.

According to COVID 19 Treatment guidelines, Criteria for giving monoclonal antibodies for SARS-CoV-2 to non hospitalized patients with COVID-19:

  1.  Patients diagnosed with a positive test for SARS-CoV-2 antigen or real-time reverse transcription nucleic acid amplification test.
  2.  Administration within 10 days of symptom onset.
  3.  Patients with High risk for deterioration.
  4.  Patients are not hospitalized for management of COVID-19.

Management of hospitalized patients includes Oxygen therapy with ventilatory support, antiviral chemotherapy, Immunomodulatory agents, and antimicrobial therapy if secondary infection or sepsis is suspected.

 Oxygen therapy, including high flow nasal cannula oxygen therapy, has decreased the length of ICU stay and hospitalization stay in general.[12]

Antiviral chemotherapy: Remdesivir the first FDA(food and drug administration) drug to treat COVID-19 in adults and pediatric patients 12 years of age and older and weighing at least 40 kg requiring hospitalization. (fda.gov).Remdesivir has shown a shorter time to clinical improvement in comparison to placebo.[13]

Anti-SARS-CoV-2 Antibodies are not authorized for use in patients with COVID 19 with the following criteria because they may be associated with worse clinical outcomes :

Patients hospitalized due to COVID -19.

Patients requiring oxygen therapy due to COVID-19.

Increase in baseline oxygen therapy requirements due to COVID -19 in patients who chronically require oxygen therapy for underlying co-morbidities(e.g., patients with chronic obstructive pulmonary disease who utilize 2 liters of oxygen chronically and after enduring COVID-19 pneumonia their requirements are up to 5 liters.)

Immunomodulators

Dexamethasone 6 mg daily for up to 10 days is indicated for hospitalized patients with COVID-19 due to survival benefits in patients receiving oxygen or invasive mechanical ventilation.[14] 

Tocilizumab and sarilumab (Interleukin-6 inhibitors):

Anti-Interleukin-6 receptor monoclonal antibodies block inflammatory protein Interleukin -6 and potentially ameliorate the cytokine storm. Interleukin -6 was detected as a key SARS-CoV cytokine involved in the overwhelming immune response exhibited in SARS-CoV infection.[15] 

Interleukin-6 receptor antagonists are not indicated in non hospitalized patients with COVID-19. 

Tocilizumab is given as 8mg/kg of actual body weight for up to 800 mg intravenous infusion, exhibiting rapid respiratory deterioration within 3 days of admission.

Contraindications:

  • Severe immunosuppression, especially in patients who recently received immunomodulating agents recently
  • Concurrent infection (including strongyloidiasis)
  • Elevated liver enzymes
  • Neutropenia
  • Thrombocytopenia

Tocilizumab (interleukin -6 receptor antagonist) was evaluated in a randomized controlled trial in patients with moderate to severe COVID-19 pneumonia (antiviral, steroids, and supplemental therapy were used in both arms of the study at the clinician discretion). Tocilizumab was used either as one dose or 2 doses 3 days apart. Tocilizumab reduced mortality and ventilation requirements on day 14 but no reduction in mortality on day 28.[16]

In another randomized controlled trial, tocilizumab was compared to standard treatment in patients hospitalized with COVID-19. Still, ICU patients were excluded, and no benefit in disease progression in the tocilizumab group was given two doses of tocilizumab 12 hours apart.[17]

Tocilizumab was also evaluated in hospitalized patients with COVID-19, excluding mechanically ventilated patients, and it did not show any improvement in mortality. Serious adverse events were higher in the tocilizumab group than in the control group.[18]

Tocilizumab did not also improve oxygenation or mortality in another randomized controlled trial.[19] When tocilizumab was used with high-dose methylprednisolone, there was a decrease in mechanical ventilation and mortality rates.[20]

Tocilizumab combined with favipiravir was shown to reduce pulmonary inflammation and mortality in patients with COVID-19.[21]

In patients with severe or critical COVID-19 pneumonia, the tocilizumab trial was stopped due to 11 deaths in the tocilizumab group versus 2 deaths in the control group at 15 days.[22]

in another randomized controlled trial, tocilizumab was used in patients with severe COVID-19 pneumonia, including patients requiring mechanical ventilation (patients with imminent death or other active infection were excluded). It did not show significant improvement in clinical condition or reduction in mortality.[23]

Tocilizumab and sarilumab (another interleukin-6 receptor antagonist) were evaluated in critically ill patients with COVID-19 ( including mechanically ventilated patients) showed improvement in clinical outcome and survival of note the patients were recruited early to the trial arms within 24 hours of starting organ support in the ICU.[24]

In a retrospective study of the use of tocilizumab without steroids in hospitalized patients with COVID-19, there was no improvement in hypoxia at day 14 or day 28.[25]

Interleukin-6 blockade sarilumab was assessed in a small open-label observational study in patients with severe COVID-19 pneumonia. There was no mortality benefit but the median time to clinical improvement was shorter. In a randomized controlled trial, sarilumab did not show clinical benefit in hospitalized patients with COVID-19. (There is no enough evidence to either recommend using  Sarilumab or against its usage currently).[26][27]

Baricitinib and Ruxolitinib (Janus-associated kinase (JAK) inhibitors)

These are not monoclonal antibodies but tyrosine kinase inhibitors, small molecule, orally available drugs. Janus-associated kinases are essential mediators for many pro-inflammatory cytokines, and JAK inhibitors have been used for many autoimmune disorders.[28]

Baricitinib has received EUA (emergency use authorization) in patients hospitalized with COVID-19 in combination with remdesivir when corticosteroids could not be used. Baricitinib is not indicated in non hospitalized patients with COVID-19. In patients hospitalized for COVID-19 pneumonia, baricitinib or tocilizumab, combined with dexamethasone alone or dexamethasone plus remdesivir showed rapid clinical deterioration in the form of elevated inflammatory markers or worsening oxygen requirements. 

Baricitinib was evaluated in a randomized controlled trial published in New England of Medicine in 03/2021:all patients received remdesivir, in the treatment group Barcitinib was added. In the control group, a placebo was given. The 28-day mortality benefit was observed in the treatment group 5.1% vs. 7.8%in the control group, and the median time to recovery was one day shorter in the treatment group.[29]

Baricitinib suppressed the immune dysregulation in patients with COVID -19 and halted the progression to severe disease in an observational study.[30]

Ruxolitinib (Janus-associated kinase (JAK) inhibitor) was evaluated in patients with severe COVID-19 pneumonia, and there was no statistical difference, but there was numerically faster clinical improvement in the ruxolitinib group.[31]

Other Issues

Trials in Progress

CD147 is a receptor on the host cell that could bind spike protein of SARS-CoV-2, so blocking CD147 could potentially block the infection of SARS-CoV-2. Mepolizumab is a humanized monoclonal antibody anti CD147 is currently being evaluated in an open-label trial to improve patients with COVID-19 pneumonia.

An ongoing randomized controlled trial evaluates ixekizumab (a monoclonal antibody that binds to Interleukin-17A) and antiviral therapy in patients hospitalized for COVID-19, excluding ICU patients.[32]

Imatinib is a tyrosine kinase inhibitor used in treating chronic myeloid leukemia and is currently being evaluated in hospitalized patients with COVID-19.[33]

Enhancing Healthcare Team Outcomes

Management of patients with COVID-19 requires a multidisciplinary team that coordinates the needs of COVID-19 patients that include:

Oxygen therapy may include pulse oximetry monitoring, supplementing oxygen according to the patients' needs via nasal cannula, high flow nasal cannula, non-invasive ventilation, and mechanical ventilation. This is managed by an interprofessional team of nurses, clinicians (including PAs and NPs), respiratory therapists, and ICU teams. Additionally, antiviral therapy such as remdesivir is managed by clinicians, nurses, and pharmacists, also operating as a cohesive unit, coordinating antiviral therapy, following guidelines, and monitoring for adverse effects. This interprofessional team approach will yield the best outcomes and facilitate data gathering as these novel treatments are used to address COVID-19 infection. [Level 5]

Monoclonal antibodies have been used in non hospitalized patients mainly prescribed by primary care providers and in patients with COVID-19 hospitalized for other reasons and at risk of deterioration from COVID -19.


Article Details

Article Author

Hend Elsaghir

Article Editor:

Ghufran Adnan

Updated:

1/25/2022 9:56:06 PM

References

[1]

Wang K,Chen W,Zhang Z,Deng Y,Lian JQ,Du P,Wei D,Zhang Y,Sun XX,Gong L,Yang X,He L,Zhang L,Yang Z,Geng JJ,Chen R,Zhang H,Wang B,Zhu YM,Nan G,Jiang JL,Li L,Wu J,Lin P,Huang W,Xie L,Zheng ZH,Zhang K,Miao JL,Cui HY,Huang M,Zhang J,Fu L,Yang XM,Zhao Z,Sun S,Gu H,Wang Z,Wang CF,Lu Y,Liu YY,Wang QY,Bian H,Zhu P,Chen ZN, CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal transduction and targeted therapy. 2020 Dec 4     [PubMed PMID: 33277466]

[2]

Petrosillo N,Viceconte G,Ergonul O,Ippolito G,Petersen E, COVID-19, SARS and MERS: are they closely related? Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2020 Jun     [PubMed PMID: 32234451]

[3]

Cascella M,Rajnik M,Aleem A,Dulebohn SC,Di Napoli R, Features, Evaluation, and Treatment of Coronavirus (COVID-19) StatPearls. 2021 Jan     [PubMed PMID: 32150360]

[4]

Castelli MS,McGonigle P,Hornby PJ, The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacology research     [PubMed PMID: 31859459]

[5]

Mulangu S,Dodd LE,Davey RT Jr,Tshiani Mbaya O,Proschan M,Mukadi D,Lusakibanza Manzo M,Nzolo D,Tshomba Oloma A,Ibanda A,Ali R,Coulibaly S,Levine AC,Grais R,Diaz J,Lane HC,Muyembe-Tamfum JJ,Sivahera B,Camara M,Kojan R,Walker R,Dighero-Kemp B,Cao H,Mukumbayi P,Mbala-Kingebeni P,Ahuka S,Albert S,Bonnett T,Crozier I,Duvenhage M,Proffitt C,Teitelbaum M,Moench T,Aboulhab J,Barrett K,Cahill K,Cone K,Eckes R,Hensley L,Herpin B,Higgs E,Ledgerwood J,Pierson J,Smolskis M,Sow Y,Tierney J,Sivapalasingam S,Holman W,Gettinger N,Vallée D,Nordwall J, A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. The New England journal of medicine. 2019 Dec 12;     [PubMed PMID: 31774950]

[6]

Andabaka T,Nickerson JW,Rojas-Reyes MX,Rueda JD,Bacic Vrca V,Barsic B, Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. The Cochrane database of systematic reviews. 2013 Apr 30     [PubMed PMID: 23633336]

[7]

Cruz-Teran C,Tiruthani K,McSweeney M,Ma A,Pickles R,Lai SK, Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy. Advanced drug delivery reviews. 2021 Feb     [PubMed PMID: 33309815]

[8]

Chen P,Nirula A,Heller B,Gottlieb RL,Boscia J,Morris J,Huhn G,Cardona J,Mocherla B,Stosor V,Shawa I,Adams AC,Van Naarden J,Custer KL,Shen L,Durante M,Oakley G,Schade AE,Sabo J,Patel DR,Klekotka P,Skovronsky DM,BLAZE-1 Investigators., SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. The New England journal of medicine. 2021 Jan 21;     [PubMed PMID: 33113295]

[9]

Gottlieb RL,Nirula A,Chen P,Boscia J,Heller B,Morris J,Huhn G,Cardona J,Mocherla B,Stosor V,Shawa I,Kumar P,Adams AC,Van Naarden J,Custer KL,Durante M,Oakley G,Schade AE,Holzer TR,Ebert PJ,Higgs RE,Kallewaard NL,Sabo J,Patel DR,Klekotka P,Shen L,Skovronsky DM, Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2021 Feb 16     [PubMed PMID: 33475701]

[10]

ACTIV-3/TICO LY-CoV555 Study Group.,Lundgren JD,Grund B,Barkauskas CE,Holland TL,Gottlieb RL,Sandkovsky U,Brown SM,Knowlton KU,Self WH,Files DC,Jain MK,Benfield T,Bowdish ME,Leshnower BG,Baker JV,Jensen JU,Gardner EM,Ginde AA,Harris ES,Johansen IS,Markowitz N,Matthay MA,Østergaard L,Chang CC,Davey VJ,Goodman A,Higgs ES,Murray DD,Murray TA,Paredes R,Parmar MKB,Phillips AN,Reilly C,Sharma S,Dewar RL,Teitelbaum M,Wentworth D,Cao H,Klekotka P,Babiker AG,Gelijns AC,Kan VL,Polizzotto MN,Thompson BT,Lane HC,Neaton JD, A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. The New England journal of medicine. 2021 Mar 11;     [PubMed PMID: 33356051]

[11]

Weinreich DM,Sivapalasingam S,Norton T,Ali S,Gao H,Bhore R,Musser BJ,Soo Y,Rofail D,Im J,Perry C,Pan C,Hosain R,Mahmood A,Davis JD,Turner KC,Hooper AT,Hamilton JD,Baum A,Kyratsous CA,Kim Y,Cook A,Kampman W,Kohli A,Sachdeva Y,Graber X,Kowal B,DiCioccio T,Stahl N,Lipsich L,Braunstein N,Herman G,Yancopoulos GD,Trial Investigators., REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. The New England journal of medicine. 2021 Jan 21     [PubMed PMID: 33332778]

[12]

Teng XB,Shen Y,Han MF,Yang G,Zha L,Shi JF, The value of high-flow nasal cannula oxygen therapy in treating novel coronavirus pneumonia. European journal of clinical investigation. 2021 Mar     [PubMed PMID: 33068293]

[13]

Spinner CD,Gottlieb RL,Criner GJ,Arribas López JR,Cattelan AM,Soriano Viladomiu A,Ogbuagu O,Malhotra P,Mullane KM,Castagna A,Chai LYA,Roestenberg M,Tsang OTY,Bernasconi E,Le Turnier P,Chang SC,SenGupta D,Hyland RH,Osinusi AO,Cao H,Blair C,Wang H,Gaggar A,Brainard DM,McPhail MJ,Bhagani S,Ahn MY,Sanyal AJ,Huhn G,Marty FM,GS-US-540-5774 Investigators., Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020 Sep 15     [PubMed PMID: 32821939]

[14]

RECOVERY Collaborative Group.,Horby P,Lim WS,Emberson JR,Mafham M,Bell JL,Linsell L,Staplin N,Brightling C,Ustianowski A,Elmahi E,Prudon B,Green C,Felton T,Chadwick D,Rege K,Fegan C,Chappell LC,Faust SN,Jaki T,Jeffery K,Montgomery A,Rowan K,Juszczak E,Baillie JK,Haynes R,Landray MJ, Dexamethasone in Hospitalized Patients with Covid-19. The New England journal of medicine. 2021 Feb 25     [PubMed PMID: 32678530]

[15]

Yoshikawa T,Hill T,Li K,Peters CJ,Tseng CT, Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. Journal of virology. 2009 Apr;     [PubMed PMID: 19004938]

[16]

Hermine O,Mariette X,Tharaux PL,Resche-Rigon M,Porcher R,Ravaud P,CORIMUNO-19 Collaborative Group., Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA internal medicine. 2021 Jan 1     [PubMed PMID: 33080017]

[17]

Salvarani C,Dolci G,Massari M,Merlo DF,Cavuto S,Savoldi L,Bruzzi P,Boni F,Braglia L,Turrà C,Ballerini PF,Sciascia R,Zammarchi L,Para O,Scotton PG,Inojosa WO,Ravagnani V,Salerno ND,Sainaghi PP,Brignone A,Codeluppi M,Teopompi E,Milesi M,Bertomoro P,Claudio N,Salio M,Falcone M,Cenderello G,Donghi L,Del Bono V,Colombelli PL,Angheben A,Passaro A,Secondo G,Pascale R,Piazza I,Facciolongo N,Costantini M,RCT-TCZ-COVID-19 Study Group., Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA internal medicine. 2021 Jan 1     [PubMed PMID: 33080005]

[18]

Salama C,Han J,Yau L,Reiss WG,Kramer B,Neidhart JD,Criner GJ,Kaplan-Lewis E,Baden R,Pandit L,Cameron ML,Garcia-Diaz J,Chávez V,Mekebeb-Reuter M,Lima de Menezes F,Shah R,González-Lara MF,Assman B,Freedman J,Mohan SV, Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. The New England journal of medicine. 2021 Jan 7;     [PubMed PMID: 33332779]

[19]

Stone JH,Frigault MJ,Serling-Boyd NJ,Fernandes AD,Harvey L,Foulkes AS,Horick NK,Healy BC,Shah R,Bensaci AM,Woolley AE,Nikiforow S,Lin N,Sagar M,Schrager H,Huckins DS,Axelrod M,Pincus MD,Fleisher J,Sacks CA,Dougan M,North CM,Halvorsen YD,Thurber TK,Dagher Z,Scherer A,Wallwork RS,Kim AY,Schoenfeld S,Sen P,Neilan TG,Perugino CA,Unizony SH,Collier DS,Matza MA,Yinh JM,Bowman KA,Meyerowitz E,Zafar A,Drobni ZD,Bolster MB,Kohler M,D'Silva KM,Dau J,Lockwood MM,Cubbison C,Weber BN,Mansour MK,BACC Bay Tocilizumab Trial Investigators., Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. The New England journal of medicine. 2020 Dec 10;     [PubMed PMID: 33085857]

[20]

Ramiro S,Mostard RLM,Magro-Checa C,van Dongen CMP,Dormans T,Buijs J,Gronenschild M,de Kruif MD,van Haren EHJ,van Kraaij T,Leers MPG,Peeters R,Wong DR,Landewé RBM, Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. Annals of the rheumatic diseases. 2020 Sep     [PubMed PMID: 32719045]

[21]

Zhao H,Zhu Q,Zhang C,Li J,Wei M,Qin Y,Chen G,Wang K,Yu J,Wu Z,Chen X,Wang G, Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2021 Jan     [PubMed PMID: 33378989]

[22]

Veiga VC,Prats JAGG,Farias DLC,Rosa RG,Dourado LK,Zampieri FG,Machado FR,Lopes RD,Berwanger O,Azevedo LCP,Avezum Á,Lisboa TC,Rojas SSO,Coelho JC,Leite RT,Carvalho JC,Andrade LEC,Sandes AF,Pintão MCT,Castro CG Jr,Santos SV,de Almeida TML,Costa AN,Gebara OCE,de Freitas FGR,Pacheco ES,Machado DJB,Martin J,Conceição FG,Siqueira SRR,Damiani LP,Ishihara LM,Schneider D,de Souza D,Cavalcanti AB,Scheinberg P,Coalition covid-19 Brazil VI Investigators., Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ (Clinical research ed.). 2021 Jan 20     [PubMed PMID: 33472855]

[23]

Rosas IO,Bräu N,Waters M,Go RC,Hunter BD,Bhagani S,Skiest D,Aziz MS,Cooper N,Douglas IS,Savic S,Youngstein T,Del Sorbo L,Cubillo Gracian A,De La Zerda DJ,Ustianowski A,Bao M,Dimonaco S,Graham E,Matharu B,Spotswood H,Tsai L,Malhotra A, Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. The New England journal of medicine. 2021 Feb 25;     [PubMed PMID: 33631066]

[24]

REMAP-CAP Investigators.,Gordon AC,Mouncey PR,Al-Beidh F,Rowan KM,Nichol AD,Arabi YM,Annane D,Beane A,van Bentum-Puijk W,Berry LR,Bhimani Z,Bonten MJM,Bradbury CA,Brunkhorst FM,Buzgau A,Cheng AC,Detry MA,Duffy EJ,Estcourt LJ,Fitzgerald M,Goossens H,Haniffa R,Higgins AM,Hills TE,Horvat CM,Lamontagne F,Lawler PR,Leavis HL,Linstrum KM,Litton E,Lorenzi E,Marshall JC,Mayr FB,McAuley DF,McGlothlin A,McGuinness SP,McVerry BJ,Montgomery SK,Morpeth SC,Murthy S,Orr K,Parke RL,Parker JC,Patanwala AE,Pettilä V,Rademaker E,Santos MS,Saunders CT,Seymour CW,Shankar-Hari M,Sligl WI,Turgeon AF,Turner AM,van de Veerdonk FL,Zarychanski R,Green C,Lewis RJ,Angus DC,McArthur CJ,Berry S,Webb SA,Derde LPG, Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. The New England journal of medicine. 2021 Feb 25;     [PubMed PMID: 33631065]

[25]

Mehta M,Purpura LJ,McConville TH,Neidell MJ,Anderson MR,Bernstein EJ,Dietz DE,Laracy J,Gunaratne SH,Miller EH,Cheng J,Zucker J,Shah SS,Chaudhuri S,Gordillo CA,Patel SR,Guo TW,Karaaslan LE,Reshef R,Miko BA,Bathon JM,Pereira MR,Uhlemann AC,Yin MT,Sobieszczyk ME, What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak. PloS one. 2021     [PubMed PMID: 33831046]

[26]

Della-Torre E,Campochiaro C,Cavalli G,De Luca G,Napolitano A,La Marca S,Boffini N,Da Prat V,Di Terlizzi G,Lanzillotta M,Rovere Querini P,Ruggeri A,Landoni G,Tresoldi M,Ciceri F,Zangrillo A,De Cobelli F,Dagna L,SARI-RAF Study Group.,SARI-RAF Study Group members., Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Annals of the rheumatic diseases. 2020 Oct     [PubMed PMID: 32620597]

[27]

Lescure FX,Honda H,Fowler RA,Lazar JS,Shi G,Wung P,Patel N,Hagino O,Sarilumab COVID-19 Global Study Group., Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Respiratory medicine. 2021 May;     [PubMed PMID: 33676590]

[28]

Schwartz DM,Kanno Y,Villarino A,Ward M,Gadina M,O'Shea JJ, JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nature reviews. Drug discovery. 2017 Dec 28;     [PubMed PMID: 29282366]

[29]

Kalil AC,Patterson TF,Mehta AK,Tomashek KM,Wolfe CR,Ghazaryan V,Marconi VC,Ruiz-Palacios GM,Hsieh L,Kline S,Tapson V,Iovine NM,Jain MK,Sweeney DA,El Sahly HM,Branche AR,Regalado Pineda J,Lye DC,Sandkovsky U,Luetkemeyer AF,Cohen SH,Finberg RW,Jackson PEH,Taiwo B,Paules CI,Arguinchona H,Erdmann N,Ahuja N,Frank M,Oh MD,Kim ES,Tan SY,Mularski RA,Nielsen H,Ponce PO,Taylor BS,Larson L,Rouphael NG,Saklawi Y,Cantos VD,Ko ER,Engemann JJ,Amin AN,Watanabe M,Billings J,Elie MC,Davey RT,Burgess TH,Ferreira J,Green M,Makowski M,Cardoso A,de Bono S,Bonnett T,Proschan M,Deye GA,Dempsey W,Nayak SU,Dodd LE,Beigel JH,ACTT-2 Study Group Members., Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. The New England journal of medicine. 2021 Mar 4;     [PubMed PMID: 33306283]

[30]

Bronte V,Ugel S,Tinazzi E,Vella A,De Sanctis F,Canè S,Batani V,Trovato R,Fiore A,Petrova V,Hofer F,Barouni RM,Musiu C,Caligola S,Pinton L,Torroni L,Polati E,Donadello K,Friso S,Pizzolo F,Iezzi M,Facciotti F,Pelicci PG,Righetti D,Bazzoni P,Rampudda M,Comel A,Mosaner W,Lunardi C,Olivieri O, Baricitinib restrains the immune dysregulation in patients with severe COVID-19. The Journal of clinical investigation. 2020 Dec 1     [PubMed PMID: 32809969]

[31]

Cao Y,Wei J,Zou L,Jiang T,Wang G,Chen L,Huang L,Meng F,Huang L,Wang N,Zhou X,Luo H,Mao Z,Chen X,Xie J,Liu J,Cheng H,Zhao J,Huang G,Wang W,Zhou J, Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. The Journal of allergy and clinical immunology. 2020 Jul     [PubMed PMID: 32470486]

[32]

Liu P,Huang Z,Yin M,Liu C,Chen X,Pan P,Kuang Y, Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial. Trials. 2020 Dec 4;     [PubMed PMID: 33276811]

[33]

Emadi A,Chua JV,Talwani R,Bentzen SM,Baddley J, Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Oct 28     [PubMed PMID: 33115543]